Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

research consortium

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

- PMLiVE

AstraZeneca and Medera’s Novoheart develop first human models of heart failure

The ‘heart-in-a-jar’ model will be used to effectively test drug candidates for HFpEF patient

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

ICR study reveals how cancers can evolve without relying on DNA mutations

The researchers found that epigenetic changes play a key role in how cancers adapt and evolve

- PMLiVE

Omnichannel scientific engagement and the use of archetypes to drive personalization

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...

Avalere Health

Springer Nature Oncologists survey report 202

[Free Report] The What, How, and When of creating content for oncologists

Create content marketing that really engages healthcare professionals.

Springer Nature

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

Patient Programmes Sponsor

Celebrating award-winning patient-centricity

Every year, Cuttsy+Cuttsy choose to sponsor 'Patient Programmes' at the PM Society Digital awards. Here's why.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer

Phase 3 trial results demonstrated a 22% reduction in risk of death versus sorafenib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links